Integra Lifesciences Holdings Corp (IART) is Reiterated by Barclays to Equal Weight, Raises Price Target to $ 74

Integra Lifesciences Holdings Corp (IART) was Reiterated by Barclays to “Equal Weight” according to the research note released today. The brokerage firm has raised the Price Target to $ 74 from a previous price target of $70 . Barclays advised their investors in a research report released on Apr 28, 2016.

On the company’s financial health, Integra Lifesciences Holdings Corp reported $0.74 EPS for the quarter, beating the analyst consensus estimate by $ 0.01 according to the earnings call on Apr 27, 2016. Analyst had a consensus of $0.73. The company had revenue of $236.80 million for the quarter, compared to analysts expectations of $230.83 million. The company’s revenue was up 1.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.76 EPS.

Integra Lifesciences Holdings Corp opened for trading at $67.68 and hit $70.89 on the upside on Wednesday, eventually ending the session at $70.78, with a gain of 7.72% or 5.07 points. The heightened volatility saw the trading volume jump to 9,78,885 shares. Company has a market cap of $2,619 M.

In a different news, on Apr 7, 2016, Stuart Essig (director) sold 21,100 shares at $66.19 per share price. According to the SEC, on May 12, 2015, Deborah A Leonetti (Corp VP, Glbl Servs & Repair) sold 2,000 shares at $64.82 per share price. On Jan 5, 2015, Judith Ogrady (CorpVP,Reg.Affairs,CorpCompli) sold 3,500 shares at $53.68 per share price, according to the Form-4 filing with the securities and exchange commission.

Integra LifeSciences Holdings Corporation is a medical technology company. The Company offers solutions such as orthopedic extremity surgery neurosurgery spine surgery and reconstructive and general surgery. The Company’s operating segments are: Specialty Surgical Solutions and Orthopedics and Tissue Technologies. The Company’s Specialty Surgical Solutions segment includes the Neurosurgery business and the Instruments business. The Company’s Orthopedics and Tissue Technologies segment includes offerings such as skin and wound repair bone and joint fixation implants in the upper and lower extremities bone grafts and nerve and tendon repair. The Company sources its handheld surgical instruments and specialty metal and pyrocarbon implants through third-party vendors. The Company manufactures its products in plants which are located in the United States Puerto Rico France Germany Ireland and Mexico.

Integra Lifesciences Holdings Corp

Leave a Reply

Integra Lifesciences Holdings Corp - Is it time to Sell?

Top Brokerage Firms are advising their investors on Integra Lifesciences Holdings Corp. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.